Aggressive high-intensity treatment approaches, including immune tolerance induction (ITI) for inhibitor eradication and prophylactic use of bypassing agents, are often indicated to mitigate bleeding risk and improve patient QoL. Highly effective treatment options are more limited for individuals with inhibitors compared with those without inhibitors.